HIV gp160 vaccine

Drug Profile

HIV gp160 vaccine

Alternative Names: 5 env5; HIVAC-1e; V env5

Latest Information Update: 21 May 2007

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer Nonindustrial source; sanofi pasteur; Transgene
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 21 May 2007 Discontinued - Phase-I for HIV infections treatment in France (unspecified route)
  • 21 May 2007 Discontinued - Phase-I for HIV infections treatment in USA (unspecified route)
  • 21 May 2007 Discontinued - Preclinical for HIV infections treatment in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top